GlaxoSmithKline PakistanKAR:GLAXO +1.66%92 ROA % is 19.95% as of Mar. 2026, which is 45% above its 10-year median of 13.77. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.26 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,004 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks better than 96.41% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. GlaxoSmithKline Pakistan's annualizedNet Income for the quarter that ended in Mar. 2026 was ₨10,443 Mil.
GlaxoSmithKline Pakistan's average Total Assets over the quarter that ended in Mar. 2026 was ₨52,337 Mil. Therefore, GlaxoSmithKline Pakistan's annualized ROA % for the quarter that ended in Mar. 2026 was 19.95%.
The historical rank and industry rank for GlaxoSmithKline Pakistan's ROA % or its related term are showing as below:
KAR:GLAXO'
s ROA % Range Over the Past 10 Years
Min: 1.45 Med: 13.77 Max: 20.94
Current: 20.8
During the past 13 years, GlaxoSmithKline Pakistan's highest ROA % was 20.94%. The lowest was 1.45%. And the median was 13.77%.
KAR:GLAXO's ROA % is ranked better than 96.41% of 1004
companies
in the Drug Manufacturers industry
Industry Median: 2.75
vs KAR:GLAXO: 20.80
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's ROA % distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a ROA % of 19.95% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on GlaxoSmithKline Pakistan and its competitors. This is 45% above median its historical median of 13.77. Over the past decade, GlaxoSmithKline Pakistan's ROA % has ranged from 1.45 to 20.94. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #36 out of 1004 companies in the Drug Manufacturers industry, placing it in the top 3.6%.
Is GlaxoSmithKline Pakistan's ROA % too high?
GlaxoSmithKline Pakistan's current ROA % of 19.95% is 45% above median its 10-year median of 13.77. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 20.94. The Drug Manufacturers industry median ROA % is 2.75. GlaxoSmithKline Pakistan's value of 19.95% is 625.5% above this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #36 out of 1004 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #36 out of 1004 companies for ROA %. This places GlaxoSmithKline Pakistan in the top 4% of its industry — outperforming the majority of peers. The industry median ROA % is 2.75. GlaxoSmithKline Pakistan's value of 19.95% is 625.5% above this benchmark. Historically, GlaxoSmithKline Pakistan's own ROA % has ranged from 1.45 to 20.94 over the past decade. While the company's 10-year median is 13.77 vs. the industry median of 2.75, GlaxoSmithKline Pakistan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.75, based on 1,004 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current ROA % of 19.95% is 625.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current ROA % is 19.95%, which is 45% above median its own 10-year median of 13.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.26, compared to a current price of ₨370.25 — trading 14.2% above its estimated fair value. The current ROA % is 19.95%, which is 45% above median its 10-year median of 13.77 and 625.5% above the Drug Manufacturers industry median of 2.75. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current ROA % is 19.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨370.25 is trading 14.2% above its estimated GF Value™ of ₨324.26.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
ROA %: 19.95% (45% above median its 10-year median of 13.77)
GF Value™: ₨324.26 vs. price of ₨370.25 (14.2% above fair value)
Industry Position: 625.5% above the Drug Manufacturers median (#36 of 1004)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score
Get the complete analysis for KAR:GLAXO
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
